Recovered patient antibody treatments against COVID-19 underway
By MYBRANDBOOK
With the continuation of the COVID-19 pandemic and possible vaccines approximately one year away from launch, the race to find a treatment for the disease continues. A growing number of pharmaceutical companies have begun work on recovered patients’ antibody treatments for COVID-19. As monoclonal antibody (mAb) drugs are some of the top sellers in the market today, this approach holds potential, says GlobalData, a leading data and analytics company.
Johanna Swanson, Product Manager at GlobalData, comments: “One approach for these treatments involves identifying the most effective anti-SARS-CoV-2 antibodies from patients who have recovered from the disease. The antibodies are then mass-produced, removing the need for continued plasma from patients, and administered intravenously to current COVID-19 patients to lessen their symptoms.”
One of the companies working on this technique is GigaGen, which is looking to produce whole antibody recombinant immunoglobulin repertoires from recovered patients. The company will use its single-cell technology libraries, which can be directly translated into antibody therapies. These antibodies would be able to block the replication of the virus and be used for passive immunity after intravenous administration. The company is currently seeking recovered patients to donate plasma to begin identification and construction of the antibody libraries. The company is also working with the FDA to speed up development with a goal of reaching clinics in early 2021.
Swanson continued: “This manufacturing process has better batch consistency and lower contamination risk because it is based on a recombinant therapy and not derived from plasma. This increases the consistency as it is not dependant on batches of human plasma, which can vary, and increases its potency as it is the same specific concentrated antibodies produced in each batch.”
Another company working on this treatment is Celltrion Group. The company has completed its identification of the most promising antibody candidates from the blood of recovered patients in Korea in partnership with the Korea Centers for Disease Control and Prevention (KCDC). The company now plans to begin work on cell line development and mass production for these antibodies, with the goal of launching clinical trials in July 2020.
Swanson continues: “This novel treatment has the potential of leveraging the body’s own immune system to create a treatment. With a large number of antibodies examined, there is a high potential to find a promising candidate that has already been selected to be effective and specific. This treatment can be used to lessen the severity of the illness for patients and to provide prophylactic treatments for healthcare workers and immunocompromised individuals.”
BREAKING NEWS
TECHNO TRENDS
Legal Battle Over IT Act Intensifies Amid Musk’s India Plans
The outcome of the legal dispute between X Corp and the Indian government c...
Wipro inks 10-year deal with Phoenix Group's ReAssure UK worth
The agreement, executed through Wipro and its 100% subsidiary,...
Centre announces that DPDP Rules nearing Finalisation by April
The government seeks to refine the rules for robust data protection, ensuri...
Home Ministry cracks down on PoS agents in digital arrest scam
Digital arrest scams are a growing cybercrime where victims are coerced or ...
E-Magazine
TECHNOTAINMENT
Hrithik Roshan to endorse RuPay as Brand Ambassador
RuPay is reportedly planning to feature Bollywood superstar Hrithik Rosha
India Today Group launches – AI Pop Stars
Staying true to our industry leadership position in using cutting-edge tech
MOVERS & SHAKERS
TelioLabs ropes in Phaniraj V A as the Group CEO
TelioLabs has announced the onboarding of Phaniraj V A as its new Group CE
Wipro Appoints Amit Kumar as Managing Partner and Global Head
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology s
OPEN YOUR EYES
INTERVIEWS
Bolstering its commitment to help build a truly self-reliant B
CP PLUS is dedicated to spreading a sense of security to every corner of In
Autodesk continually pushing the boundaries in the Design and
Autodesk’s vision is of a better world designed and made for all. It inte
HOT PICK
MSI Announces the availability of RTX 50 series of laptops in
MSI, the innovative computing manufacturer in gaming, creator
Nothing Phone (3a) goes on sale today, starting at Rs 19,999
The phone was launched on March 4, featuring a 50MP main, ultra-wide, and t
MAKE IN INDIA BRANDS
BEETEL TELETECH LTD.
NETWEB TECHNOLOGIES INDIA LTD.
QUICK HEAL TECHNOLOGIES PVT. LTD.
STERLITE TECHNOLOGIES LTD.
EMINENT CIO'S OF INDIA
ICONS OF INDIA
ICONS OF INDIA : SHAILENDER KUMAR
Shailender Kumar is senior vice president and regional managing direct...
Icons Of India : CP Gurnani
Former Managing Director and CEO of the well-known IT service company ...
ICONS OF INDIA : SOM SATSANGI
With more than three decades in the IT Sector, Som is responsible for ...
PARTNER SPEAKERS
PSU
GeM - Government e Marketplace
GeM is to facilitate the procurement of goods and services by various ...
GSTN - Goods and Services Tax Network
GSTN provides shared IT infrastructure and service to both central and...
C-DOT - Center of Development of Telematics
India’s premier research and development center focused on telecommu...
VIDEOS
Top 25 Brands
Global Indian industry
Indian Tech Talent Excelling The Tech World - Aneel Bhusri, CEO, Workday
Aneel Bhusri, Co-Founder and Executive Chair at Workday, has been a le...
Indian Tech Talent Excelling The Tech World - Aman Bhutani, CEO, GoDaddy
Aman Bhutani, the self-taught techie and CEO of GoDaddy, oversees a co...
Indian Tech Talent Excelling The Tech World - REVATHI ADVAITHI, CEO- Flex
Revathi Advaithi, the CEO of Flex, is a dynamic leader driving growth ...
ITFORUM 2025
CMO of the Year
WOMEN LEADERSHIP
IMAGE GALLERY
.jpg)
TRENDS IN TECHNOLOGY
MORE VIDEOS
ADVERTISEMENTS
TECHNOLOGY DISRUPTION
UNICORNS REVOLUTIONISING
of images belongs to the respective copyright holders
